General Catalyst Global Resilience Merger Corp. (GCGR) Stock Price

10.07 +0.00 (+0.00%)
Open: 10.05 Vol: 380.94K Day's range: 10.05 - 10.07 Jun 29, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
GCGR Technical Analysis
5 mins 30 mins Hourly Daily Weekly
NEUTRAL NEUTRAL NEUTRAL NEUTRAL NEUTRAL
  5 mins 30 mins Hourly Daily Weekly
MA5 N/A     N/A     N/A     N/A     N/A    
MA10 N/A     N/A     N/A     N/A     N/A    
MA20 N/A     N/A     N/A     N/A     N/A    
MA50 N/A     N/A     N/A     N/A     N/A    
MA100 N/A     N/A     N/A     N/A     N/A    
MA200 N/A     N/A     N/A     N/A     N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD N/A     N/A     N/A     N/A     N/A    
RSI N/A     N/A     N/A     N/A     N/A    
STOCH N/A     N/A     N/A     N/A     N/A    
WILL %R N/A     N/A     N/A     N/A     N/A    
CCI N/A     N/A     N/A     N/A     N/A    
Latest Filters Detected On GCGR
General Catalyst Global Resilience Merger Corp. News
General Catalyst Global Resilience Merger Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing on June 22, 2026
Tuesday, June 16, 2026 03:42 PM
General Catalyst Global Resilience Merger Corp. (NASDAQ: GCGRU) (the “Company”), a blank check company, today announced that, commencing June 22, 2026, holders of the Company’s GRAIL securities ...
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
Tuesday, January 20, 2026 01:01 AM
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing ...
NeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American ...
Tuesday, June 13, 2023 01:01 AM
BOSTON, June 13, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that data ...
GCGR historical stock data
date open high low close volume
29/06/26 10.05 10.07 10.05 10.07 380,939
Quote Details
52wk Low:10.05
52wk High:10.07
Vol:380.94K
Avg Vol(3m):380.9K
1Y Chng:+0.00%
1M Chng:+0.00%
Add to Watch List
More Information
Sector N/A
Index N/A
Market Cap. 0.00